Is testosterone replacement therapy appropriate for a patient with a prior history of venous or arterial thrombosis?

Testosterone Therapy in Patients with Prior Blood Clots

Testosterone replacement therapy can be cautiously considered in patients with a prior history of thrombosis, but requires rigorous risk stratification, close monitoring, and is particularly high-risk in the first 6 months of treatment.

Risk Assessment Framework

The decision hinges on several critical factors that must be evaluated before initiating therapy:

Absolute Contraindications

• Active thrombophilia with recurrent events: Patients with documented thrombophilia who experienced recurrent thromboses despite anticoagulation while on testosterone should not receive TRT 1. Two case reports demonstrated recurrent DVT-PE events (3 events over 11 months in one patient, 2 events over 2 months in another) despite adequate anticoagulation when testosterone was continued.

High-Risk Scenarios Requiring Extreme Caution

• Hematocrit >48% (>50% at high altitude) represents a moderate-to-high risk contraindication 2
• Undiagnosed thrombophilia: 76% of patients who developed VTE on testosterone had underlying thrombophilia versus 19% of controls 1. Screening before initiation is prudent in patients with prior clots.
• Recent thrombotic event (<6 months): The highest VTE risk occurs in the first 6 months of testosterone therapy, with a rate ratio of 1.63 (95% CI 1.12-2.37), corresponding to 10 additional VTE events per 10,000 person-years 3

Evidence Synthesis

The data presents a nuanced picture:

Short-term risk (0-6 months): Population-based case-control studies demonstrate a clear increased risk in early treatment 3. This risk was observed across all patient subgroups, including those with and without pathological hypogonadism (RR 1.52 vs 1.88) and with or without known VTE risk factors (RR 1.41 vs 1.91).

Long-term risk (>6 months): After 6 months of treatment, the rate ratio normalizes to 1.00 (95% CI 0.68-1.47) 3. Meta-analyses of RCTs show no significant increase in VTE risk overall (OR 1.42,95% CI 0.22-9.03) 4, though confidence intervals are wide.

Guideline perspective: The 2018 Endocrine Society guidelines note that case-control studies have not shown consistent VTE risk increases, but acknowledge FDA warnings about VTE risk, particularly in the first 6 months and in patients with thrombophilia 2.

Clinical Management Algorithm

If Proceeding with Testosterone Therapy:

1. Pre-treatment evaluation:

   • Screen for thrombophilia (Factor V Leiden, prothrombin G20210A, Factor VIII, homocysteine, antiphospholipid antibodies) in patients with prior unprovoked VTE 1
   • Baseline hematocrit must be <48%
   • Document cardiovascular risk factors

2. Formulation selection:

   • Prefer transdermal preparations over intramuscular injections: Erythrocytosis occurs in 15.4% with patches versus 43.8% with IM injections 5
   • Dose-dependent risk: 2.8% erythrocytosis with 5mg/day patches, 11.3% with 50mg/day gel, 17.9% with 100mg/day gel 5

3. Monitoring protocol:

   • Months 1-6 (highest risk period):
     • Hematocrit/hemoglobin at months 1,3, and 6
     • Most changes occur in first 3 months 5
   • After 6 months: Every 6-12 months
   • Intervention thresholds: If hematocrit rises above normal range, implement dose reduction, withhold testosterone, therapeutic phlebotomy, or blood donation 5

4. Anticoagulation considerations:

   • Continue therapeutic anticoagulation if already prescribed for prior VTE
   • Critical caveat: Anticoagulation does NOT eliminate recurrence risk in thrombophilic patients on testosterone 1
   • Consider prophylactic anticoagulation during the first 6 months in very high-risk patients

Common Pitfalls to Avoid

• Supraphysiologic dosing: 60% of VTE cases had testosterone >800 ng/dL and 78% had estradiol >42.6 pg/mL 1. Target physiologic replacement only.
• Ignoring hematocrit elevation: Even mild erythrocytosis increases blood viscosity and can aggravate vascular disease, particularly in elderly patients with coronary, cerebrovascular, or peripheral vascular disease 5
• Continuing therapy after VTE: If VTE occurs on testosterone, strongly consider permanent discontinuation, especially if thrombophilia is present 1

Special Populations

Patients with COPD or conditions causing baseline elevated hematocrit: Risk of hemoconcentration is substantially greater; testosterone may be contraindicated 5

Elderly patients with vascular disease: Increased blood viscosity from erythrocytosis poses grave consequences for coronary, cerebrovascular, and peripheral circulation 5

Bottom Line

While the overall RCT evidence suggests testosterone may be safe from a VTE perspective in unselected populations 6, 4, the first 6 months represent a critical high-risk window 3. In patients with prior thrombosis, the risk-benefit calculation requires careful consideration of hypogonadal symptoms severity, presence of thrombophilia, baseline hematocrit, and ability to maintain close monitoring. The presence of documented thrombophilia with prior unprovoked VTE should prompt serious reconsideration of testosterone therapy altogether.